Candon S, Guerrot D, Drouot L, et al. - Assuming a higher risk for severe forms of COVID‐19 among immunosuppressed organ transplanted patients, researchers sought to report the first assessment on the immune response to SARS‐CoV‐2 in transplanted patients. Here, 11 kidney transplanted patients recovered from RT‐PCR‐confirmed (n = 5) or initially suspected (n = 6) COVID‐19 were assessed for antibody and T cell responses to SARS‐CoV‐2. Decrease in immunosuppressive therapy among RT‐PCR‐confirmed COVID‐19 transplant patients allowed them to exhibit mount vigorous antiviral T cell and antibody responses, as efficiently as two non‐therapeutically immunosuppressed COVID‐19 patients on hemodialysis. In contrast, no antibody response was evident in six RT‐PCR‐negative patients. Among them, there were either very low numbers of SARS‐CoV‐2‐reactive T cells or no T cell response, potentially ruling out COVID‐19 diagnosis. Seronegative healthy controls without known exposure to the virus also showed low levels of T cell reactivity to SARS‐CoV‐2. Results thereby suggest that during COVID‐19, monitoring both T cell and serological immunity might allow the differential diagnosis of COVID‐19 but are also required to determine the potential role of antiviral T cells in the development of severe forms of the disease.